Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.49 |
| ▸ | CDK8 | P49336 | 3/20 | 0.48 |
| ▸ | CCNC | P24863 | 2/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.47 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.46 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.39 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30369707 | 1.00 | PDE5A (0.49) | PDE5ACDK8CCNCMAPKAPK2GAK | |
| SCHEMBL13914471 | 0.87 | MAPKAPK2 (0.62) | PDE5AMAPKAPK2DYRK1BMAP4K4 | |
| SCHEMBL2208188 | 0.86 | GAK (0.46) | PDE5ACDK8CCNCMAPKAPK2GAK | |
| SCHEMBL23999965 | 0.82 | EGFR (0.46) | PDE5ACDK8CCNCMAPKAPK2GAK | |
| SCHEMBL29843782 | 0.79 | CDK8 (0.48) | PDE5ACDK8CCNCMAPKAPK2GAK | |
| SCHEMBL29843629 | 0.79 | SLC22A12 (0.51) | PDE5ACDK8CCNCMAPKAPK2GAK | |
| SCHEMBL23625624 | 0.79 | CDK8 (0.48) | PDE5ACDK8CCNCMAPKAPK2GAK | |
| SCHEMBL981901 | 0.79 | CDK8 (0.51) | PDE5ACDK8CCNCMAPKAPK2GAK | |
| SCHEMBL633785 | 0.79 | CDK8 (0.48) | PDE5ACDK8CCNCMAPKAPK2GAK | |
| SCHEMBL1147915 | 0.79 | SLC22A12 (0.51) | PDE5ACDK8CCNCMAPKAPK2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127906-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | UNIVERSITY OF SOUTH CAROLINA | 2025-04-24 | — | — | US | disclosed |
| US-12281080-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2025-04-22 | — | — | US | disclosed |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-112088157-B | Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors | 拉文纳制药公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| US-6911469-B2 | Sulfonamide compounds and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| EP-1481978-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | Mitsubishi Rayon Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| CN-1268942-A | Sulfonamide compounds and medicinal use thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-10-04 | — | — | CN | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-4396620-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | disclosed |
| US-4382931-A | 3'-Substituted quinolinium cephalosporins | ELI LILLY AND COMPANY (US) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127906-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | CDK8, CDK9, CDK18 | PDE5A 4345/4885CDK8 1/4885CCNC 109/4885 |
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | PDE5A 916/4885CDK8 550/4885CCNC 788/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | PDE5A 938/4885CDK8 567/4885CCNC 821/4885 |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | PDE5A 10/4885CDK8 2415/4885CCNC 4313/4885 |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | PIN4, IPO5, HLCS | PDE5A 4680/4885CDK8 2130/4885CCNC 1069/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | PDE5A 1233/4885CDK8 385/4885CCNC 491/4885 |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PIP5K1C | PDE5A 1811/4885CDK8 1413/4885CCNC 2067/4885 |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | PDE5A 10/4885CDK8 2106/4885CCNC 3448/4885 |
| US-12281080-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | CDK8, CDK9, CDK19 | PDE5A 2279/4885CDK8 1/4885CCNC 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.